{"groups":[{"description":"Vandetanib 300 mg/day oral","id":"FG000","title":"Vandetanib"},{"description":"Vinorelbine 30 mg/m2 iv, administrated weekly","id":"FG001","title":"Vinorelbine"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"1"}],"type":"Adverse Event"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"2"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"}],"type":"Physician Decision"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"}],"type":"Lost to Follow-up"},{"reasons":[{"groupId":"FG000","numSubjects":"11"},{"groupId":"FG001","numSubjects":"6"}],"type":"Progressive disease"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"14"},{"groupId":"FG001","numSubjects":"11"}],"type":"STARTED"},{"achievements":[{"comment":"Randomised patients ongoing study treatment at data cut-off","groupId":"FG000","numSubjects":"0"},{"comment":"Randomised patients ongoing study treatment at data cut-off","groupId":"FG001","numSubjects":"0"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"14"},{"groupId":"FG001","numSubjects":"11"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"recruitmentDetails":"First subject enrolled: 17 December 2007, Last subject last visit: 22 July 2009.\n\nThe study was conducted at 2 centres in Switzerland and 4 centres in Germany."}